Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Raises $75 Million to Develop Oncology Drugs in China

publication date: Nov 14, 2014
BeiGene, a novel drug development company located in Beijing, raised $75 million in a series A funding. BeiGene has three oncology drug candidates in Phase I testing, and it has sold ex-China rights for two of them to Merck Serono in deals that are worth as much as $232 million each. In addition, it secured a large, though undisclosed, investment from the US pharma Merck in 2011. BeiGene has made substantial progress in its first four years: it is a remarkably mature company to be announcing its first VC fundraising round. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital